Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1984 1
2010 1
2014 1
2015 3
2016 1
2017 1
2018 1
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Methotrexate-induced immune haemolytic anaemia.
Woolley PV 3rd, Sacher RA, Priego VM, Schanfield MS, Bonnem EM. Woolley PV 3rd, et al. Among authors: priego vm. Br J Haematol. 1983 Aug;54(4):543-52. doi: 10.1111/j.1365-2141.1983.tb02132.x. Br J Haematol. 1983. PMID: 6871106
ECLIPSE-PV: A Randomized, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Two Dosing Regimens of Ropeginterferon Alfa-2b-Njft in Polycythemia Vera.
Mascarenhas J, Bose P, Hillis C, Yacoub A, El Chaer F, Maze D, Abu-Zeinah G, Qin A, Priego V, Tashi T, Cerquozzi S, Babu S, Foltz L, Goel S, Bhave RR, Lee S, Oh ST, Reeves B, Benton C, Fletcher L, Sirhan S, Safah H, Salib H, Villeneuve PJA, Zagrijtschuk O, Castro H, Masarova L. Mascarenhas J, et al. Among authors: priego v. Acta Haematol. 2025 Mar 5:1-7. doi: 10.1159/000544818. Online ahead of print. Acta Haematol. 2025. PMID: 40043697
TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer.
Yardley DA, Arrowsmith ER, Daniel BR, Eakle J, Brufsky A, Drosick DR, Kudrik F, Bosserman LD, Keaton MR, Goble SA, Bubis JA, Priego VM, Pendergrass K, Manalo Y, Bury M, Gravenor DS, Rodriguez GI, Inhorn RC, Young RR, Harwin WN, Silver C, Hainsworth JD, Burris HA 3rd. Yardley DA, et al. Among authors: priego vm. Breast Cancer Res Treat. 2017 Aug;164(3):649-658. doi: 10.1007/s10549-017-4285-6. Epub 2017 May 15. Breast Cancer Res Treat. 2017. PMID: 28508185 Clinical Trial.
Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase II trial of the Sarah Cannon Research Institute.
Yardley DA, Bosserman LD, O'Shaughnessy JA, Harwin WN, Morgan SK, Priego VM, Peacock NW, Bass JD, Burris HA 3rd, Hainsworth JD. Yardley DA, et al. Among authors: priego vm. Breast Cancer Res Treat. 2015 Nov;154(1):89-97. doi: 10.1007/s10549-015-3599-5. Epub 2015 Oct 12. Breast Cancer Res Treat. 2015. PMID: 26456573 Clinical Trial.